Lars Abrahmsén
Technik-/Wissenschafts-/F&E-Leiter bei Akinion Pharmaceuticals AB
Ursprung des Netzwerks ersten Grades von Lars Abrahmsén
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 19 | |
Akinion Pharmaceuticals AB
 Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden.
12
| Holding Company | Pharmaceuticals: Major | 12 |
KDev Oncology AB
 KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden.
7
| Holding Company | Miscellaneous Commercial Services | 7 |
Affibody AB
 Affibody AB Miscellaneous Commercial ServicesCommercial Services Affibody AB conducts research and development services within biotechnology. It markets and sells licensed products and research findings to the pharmaceutical industry. The company was founded by Karin Nord in 1998 and is headquartered in Stockholm, Sweden.
5
| Subsidiary | Miscellaneous Commercial Services | 5 |
| Extinct | Pharmaceuticals: Major | 5 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Lars Abrahmsén
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| AMGEN INC. | Pharmaceuticals: Major | Director of Finance/CFO Corporate Officer/Principal | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Sales & Marketing | |
| JOHNSON & JOHNSON | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Medarex, Inc.
 Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | Miscellaneous Commercial Services | Director of Finance/CFO Director of Finance/CFO | |
| INTEGRA LIFESCIENCES HOLDINGS CORPORATION | Medical Specialties | Director/Board Member Director of Finance/CFO | |
The Wellcome Trust Ltd.
 The Wellcome Trust Ltd. Investment Trusts/Mutual FundsMiscellaneous The Wellcome Trust Ltd. engages welfare and charitable services. It supports the discovery of vaccines and drug-resistant infections, diversity and inclusion, open research, government investment in research, data sharing in public health emergencies, and strengthening ecosystems. The company was founded by Henry Wellcome in 1936 and is headquartered in London, UK. | Investment Trusts/Mutual Funds | Corporate Officer/Principal Chief Executive Officer | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal Corporate Officer/Principal | |
| TENGION, INC. | Biotechnology | Director/Board Member Corporate Officer/Principal | |
HealthCap AB
 HealthCap AB Investment ManagersFinance HealthCap AB (HealthCap) is a venture capital subsidiary of Odlander, Fredrikson & Co. AB founded in 1995 by Björn Ingemar Odlander and Peder Fredrikson. The firm is headquartered in Stockholm, Sweden with an additional office in Switzerland. | Investment Managers | Private Equity Investor Private Equity Investor | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Undergraduate Degree Doctorate Degree | |
| KARO PHARMA AB (PUBL) | Pharmaceuticals: Major | Chairman Director of Finance/CFO | |
| BIOTAGE AB | Medical Specialties | Director of Finance/CFO Director of Finance/CFO | |
Odlander, Fredrikson & Co. AB
 Odlander, Fredrikson & Co. AB Financial ConglomeratesFinance Odlander Fredrikson & Co. AB provides financial support services. The company was founded in 1996 and is headquartered in Stockholm, Sweden. | Financial Conglomerates | Corporate Officer/Principal Corporate Officer/Principal | |
| University of Oxford | College/University | Doctorate Degree Undergraduate Degree | |
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
| Karolinska Institutet | College/University | Director/Board Member Director/Board Member Doctorate Degree Doctorate Degree Corporate Officer/Principal Doctorate Degree | |
| OREXO AB | Pharmaceuticals: Major | Chairman Director/Board Member | |
SEB Venture Capital
 SEB Venture Capital Investment ManagersFinance SEB Venture Capital (SEB Venture Capital) is a venture capital subsidiary of Skandinaviska Enskilda Banken AB founded in 1995. The firm is headquartered in Stockholm, Sweden. | Investment Managers | Corporate Officer/Principal Corporate Officer/Principal | |
| Princeton University | College/University | Corporate Officer/Principal Undergraduate Degree Undergraduate Degree | |
| Stockholm School of Economics | College/University | Graduate Degree Graduate Degree Masters Business Admin | |
Karolinska Development AB (Private Equity)
 Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | Investment Managers | Chief Executive Officer Chief Executive Officer | |
Biolipox AB
 Biolipox AB Pharmaceuticals: MajorHealth Technology Biolipox AB develops and manufactures pharmaceuticals products. The company engages in the research and development of pharmaceuticals for the treatment of respiratory and other inflammatory diseases such as asthma, chronic obstructive pulmonary disease, rhinitis, pain, and arthritis. It was founded in June 2000 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chairman President | |
Newron Sweden AB
 Newron Sweden AB Pharmaceuticals: MajorHealth Technology Newron Sweden AB is a biopharmaceutical company engaged in the development of novel therapies for the treatment of disorders of the central nervous systems. The company was founded by Jonas Cristopher Frisen and Ann Marie Janson in 1998 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Chairman Corporate Officer/Principal | |
| ONCOPEPTIDES AB | Pharmaceuticals: Major | Director/Board Member Director of Finance/CFO General Counsel | |
| University of Lund | College/University | Corporate Officer/Principal Doctorate Degree Graduate Degree | |
Rosetta Capital Ltd.
 Rosetta Capital Ltd. Investment ManagersFinance Rosetta Capital Ltd (Rosetta Capital) is a venture capital firm is founded in 2001 by Jeremy Curnock Cook, Michael Forer and Jonathan Hepple. The firm is headquartered in London. | Investment Managers | Founder Private Equity Investor Investment Committee Member Private Equity Investor | |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chairman Director/Board Member Chief Executive Officer Director/Board Member Director/Board Member Director/Board Member Director/Board Member Director/Board Member Director/Board Member Corporate Officer/Principal Director of Finance/CFO Corporate Officer/Principal | |
| Harvard Medical School | College/University | Corporate Officer/Principal Doctorate Degree Corporate Officer/Principal | |
Roche AB
 Roche AB Pharmaceuticals: MajorHealth Technology Part of Roche Holding AG, Roche AB is a biotechnology company founded in 1896. The company is based in Solna, Sweden and creates innovative treatments to help millions of patients worldwide. Roche actively seeks partnerships with healthcare providers, academia, patient associations, organizations, external companies, and startups to identify needs that form the basis for collaborations. Roche is one of the world's largest research-based biotechnology companies, focusing on advancing science to improve people's lives. The Swedish company develops both drugs and diagnostics and has great respect for the multiple perspectives required to create tomorrow's healthcare. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Targovax Oy
 Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
ClanoTech AB
 ClanoTech AB Pharmaceuticals: MajorHealth Technology ClanoTech AB is a holding company that develops drugs for the treatment of cancer and macular degeneration. Its lead candidate is an inhibitor of the alpha5beta1-integrin receptor which is present in fibroblast and on vascular endothelial cells. Its Alpha5beta1-integrin is strongly up-regulated in fibroblast when switching to the fibrotic state and in scars after glaucoma surgery. Its strategy spans from therapeutic areas with high commercial potential as wet Age Regulated Macular Degeneration to ophthalmology niche indications with orphan drug opportunity such as developing advent in glaucoma surgery techniques. The company was founded by Yihai Cao in 2006 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member Comptroller/Controller/Auditor Corporate Officer/Principal | |
| SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Chairman Corporate Officer/Principal | |
| BLUEPRINT MEDICINES CORPORATION | Biotechnology | Chairman Chief Tech/Sci/R&D Officer | |
| KAROLINSKA DEVELOPMENT AB | Financial Conglomerates | Chief Tech/Sci/R&D Officer Chief Executive Officer Director/Board Member Chairman General Counsel | |
Modus Therapeutics AB
 Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member Director/Board Member | |
| MODUS THERAPEUTICS HOLDING AB | Biotechnology | Chairman Director/Board Member | |
KDev Investments AB
 KDev Investments AB BiotechnologyHealth Technology KDev Investments AB engages in research, sales, and development in the fields of medicine, biotechnology, pharmaceuticals, and medical technology. It also owns and manages investments of companies in the fields of medicine. Its portfolio will include both early and clinical stage pharmaceutical assets, as well as some technology assets. The company was founded on January 10, 2012 and is headquartered in Solna, Sweden. | Biotechnology | Chairman Chairman Director/Board Member Director/Board Member | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Masters Business Admin | |
| Kellogg School of Management | College/University | Doctorate Degree Masters Business Admin | |
Atrin Pharmaceuticals LLC
 Atrin Pharmaceuticals LLC BiotechnologyHealth Technology Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA. | Biotechnology | Director/Board Member Founder Director/Board Member Director/Board Member | |
| VOR BIOPHARMA INC. | Biotechnology | Director/Board Member Chief Tech/Sci/R&D Officer | |
Atrin Pharmaceuticals, Inc.
 Atrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 2012, Atrin Pharmaceuticals, Inc. is a DNA Damage Response development company that focuses on a pipeline of products resulting from a series of novel conformationally restricted macrocyclic molecules. Part of Aprea Therapeutics, Inc., the company is based in Doylestown, PA. Atrin Pharmaceuticals was acquired by Aprea Therapeutics, Inc. on May 16, 2022 for $1.33 million. The company's products have the highest known potency for inhibiting ATR and exhibit ATR selectivity with potential broad therapeutic profile. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal Chief Executive Officer Director/Board Member Director/Board Member Chief Operating Officer | |
Novira Therapeutics LLC
 Novira Therapeutics LLC Pharmaceuticals: MajorHealth Technology Novira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of therapies for the treatment of chronic hepatitis B (CHB) infection. The firm’s novel antiviral drug candidates addresses the limitations of CHB therapies. The company was founded in 2009 by Osvaldo Flores, Ali Munawar and George D. Hartman and is headquartered in Doylestown, PA. | Pharmaceuticals: Major | Chairman Chief Executive Officer Chief Operating Officer |
Statistik
International
| Schweden | 27 |
| Vereinigte Staaten | 20 |
| Vereinigtes Königreich | 4 |
| Dänemark | 2 |
| Finnland | 2 |
Sektoral
| Health Technology | 31 |
| Consumer Services | 10 |
| Finance | 7 |
| Commercial Services | 4 |
| Miscellaneous | 2 |
Operativ
| Director/Board Member | 281 |
| Corporate Officer/Principal | 118 |
| Chairman | 72 |
| Independent Dir/Board Member | 61 |
| Chief Executive Officer | 48 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Viktor Drvota | 41 |
| Johan Rutger Christenson | 35 |
| Scott Rocklage | 32 |
| Håkan Åström | 26 |
| Bernd Seizinger | 23 |
| Guido Magni | 23 |
| Torsten Rüdiger Goesch | 23 |
| Erika Johanna Söderberg Johnson | 21 |
| Carl-Johan Dalsgaard | 21 |
| Terje Kalland | 20 |
| Jonathan Hepple | 19 |
| Michael Kelly | 19 |
| Joseph Anderson | 19 |
| Christian Schade | 18 |
| Michael Forer | 18 |
- Börse
- Insiders
- Lars Abrahmsén
- Unternehmensverbindungen
